Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23

The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reasso...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Chuang, Erica SY, Sabaiduc, Suzana, Kaweski, Samantha E, Kim, Shinhye, Dickinson, James A, Olsha, Romy, Gubbay, Jonathan B, Zelyas, Nathan, Charest, Hugues, Bastien, Nathalie, Jassem, Agatha N, De Serres, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896608/
https://www.ncbi.nlm.nih.gov/pubmed/36729117
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.5.2300043
Descripción
Sumario:The Canadian Sentinel Practitioner Surveillance Network estimated vaccine effectiveness (VE) during the unusually early 2022/23 influenza A(H3N2) epidemic. Like vaccine, circulating viruses were clade 3C.2a1b.2a.2, but with genetic diversity affecting haemagglutinin positions 135 and 156, and reassortment such that H156 viruses acquired neuraminidase from clade 3C.2a1b.1a. Vaccine provided substantial protection with A(H3N2) VE of 54% (95% CI: 38 to 66) overall. VE was similar against H156 and vaccine-like S156 viruses, but with potential variation based on diversity at position 135.

Ejemplares similares